Back

Semaglutide eligibility in chronic coronary syndrome: are patients without prior myocardial infarction at comparable risk to the SELECT trial population?

30 August 2026 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Epidemiology and risk assessment in patients with chronic coronary syndrome Epidemiology, Prognosis, Outcome ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Pernille Tilma Tonnesen

Aarhus University Hospital, Aarhus (Denmark)

5 More presentations in this session

Presentation thumbnail
Beyond all-cause mortality: reduction of coronary deaths after CABG - MASS Registry analysis
Mrs M. Stanislavovna Tairova (Sao Paulo, BR)
Abstract Slides
Presentation thumbnail
Lipoprotein(a) and extent of coronary artery disease in patients undergoing PCI
Professor D. Tousoulis (Athens, GR)
Abstract Slides
Presentation thumbnail
Evolution of anthropometrics parameters in overweight patients with chronic coronary syndromes
Doctor J. Mesnier (Paris, FR)
Abstract Slides
Presentation thumbnail
Impact of anthropometric parameters in patients with chronic coronary syndromes: insights from the CLARIFY registry
Doctor J. Mesnier (Paris, FR)
Abstract Slides
Presentation thumbnail
An integrative clinical-radiomic model for predicting recurrent angina based on dual-energy coronary CT angiography
Doctor W. Tang (Zhuhai, CN)
Abstract Slides

Access the full session

Session thumbnail
Epidemiology and risk assessment in patients with chronic coronary syndrome

The Event

Event poster

ESC Congress 2026

30 August 2026 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Effects of once-weekly semaglutide on coronary outcomes in patients with type 2 diabetes mellitus with or at high risk for cardiovascular disease: insights from the SUSTAIN-6 trial
7 April 2022
thumbnail
Congress Presentation
Deescalating measures for chronic coronary syndrome: as stable as an atherosclerotic plaque can be.
29 June 2021
thumbnail
Congress Presentation
Prevalence of SELECT-eligibility and incidence of 5-year major adverse cardiovascular outcomes in non-diabetic patients with myocardial infarction
27 August 2023
thumbnail
Congress Presentation
Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities
3 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources